Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 30 IN PLASTIC CONTAINER versus DEXTROSE 38 5 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: DEXTROSE 30 IN PLASTIC CONTAINER versus DEXTROSE 38 5 IN PLASTIC CONTAINER.
DEXTROSE 30% IN PLASTIC CONTAINER vs DEXTROSE 38.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose (D-glucose) is a monosaccharide that serves as a substrate for cellular energy production. It is metabolized via glycolysis and the citric acid cycle to produce ATP, and it also participates in the pentose phosphate pathway for NADPH and ribose synthesis.
Dextrose is a simple sugar that provides caloric support and serves as a source of energy. It increases blood glucose levels, which is essential for cellular metabolism, particularly in the brain and erythrocytes.
Intravenous administration; dose depends on patient's metabolic needs and clinical condition. Typical adult dose: 500 mL of 30% dextrose (150 g dextrose) infused over 4-6 hours, rate not exceeding 0.5 g/kg/hour. Frequency: as needed per blood glucose monitoring.
Intravenous administration. Dose depends on clinical condition; typically 50-100 mL of 38.5% dextrose (19.25-38.5 g glucose) for hypoglycemia. Maximum infusion rate: 0.5 g/kg/h.
None Documented
None Documented
Not applicable; dextrose is a physiologic sugar with rapid metabolism. In diabetics, impaired utilization may prolong glucose elevation (clinical context: risk of hyperglycemia).
~30 minutes (endogenous glucose turnover; clinical context: continuous infusion required for maintenance as glucose is rapidly metabolized)
Dextrose is completely metabolized to carbon dioxide and water; <5% excreted unchanged in urine (renal) and none via biliary/fecal routes.
100% renal (excreted as carbon dioxide and water after metabolism; negligible unchanged glucose in urine under normoglycemia; renal threshold ~180 mg/dL)
Category C
Category C
IV Fluid
IV Fluid